FOLH1 and prostate cancer: This work aims to establish a method to produce 43Sc and 47Sc, label it with PSMA-617 as 43Sc/47-Sc-PSMA-617, and investigate its utilization in a preclinical PSMA-positive prostate cancer model via PET and SPECT imaging studies.